Member Info for BuenaVista

Who knows. It's about promoting Avacta and the platform as much as about any individual prodrug candidate.

This isn't until April 16th and has been posted already...

Of course not. It's obvious that Garonne lies for a living. A vile human being. Anyone who is influenced by it deserves all the losses they'll get.

Is there a special change-of-tax-year TA module?

VK, if you are serious, then I'm sorry about your late wife. We've just about all of us suffered loss of family and friends to cancer. But if you are serious about Avacta then you need to educate yourself by doing your own research about the AVA6000 trial and the rest of what Avacta has.

Start with the ALS-6000-101 Phase 1a Clinical Study Update from Science Day
https://stream.brrmedia.co.uk/broadcast/63d3f8211874497653f33965

And then follow a few of the video presentations in the 'Other Company Presentations and Videos' section on the Investor Resources page
https://avacta.com/investors/documents-presentations/

Remember though that if you decline to educate yourself you will continue to be called a twat. ;0))

And there are two reasons for that: so that the patients are anthracycline-naive; and the Phase 1a part of the trial is about safety, tolerabilty, PK and PD, not about shrinking the metastatic tumours or end-of-life patients.

Avacta up today, bounced off the 108 bottom. Other techs on AIM generally up. Big move up for biotech stocks on NASDAQ yesterday. Why? News influencing the market or just a change of sentiment, temporary or otherwise?

Thank you JT for taking the initiative and reporting here what Alan said.

Massive amounts of doxorubicin administered without the usual terrible side effects might be a news story of hope but would it be statistically significant? I mean, on up to 12 terminally ill patients. Different if at least one of them manages to pull through but I think Avacta will prefer to wait until into Phase 1b when statistically relevant efficacy and, more importantly, direct comparison with plain doxorubicin can be shown in a treatment environment.

RMFatGB, the status of Avacta being funded to 2024 and beyond is now called into question. That was the situation when it was stated but since then the planned Phase 1a has completed and the planned Phase 1b is being abandoned in favour of an extension of 1a by two cohorts (and very likely to a new design) and a completely new and expanded 1b. Whether the new trial plan will be more or less expensive than the abandoned one will, I suspect, depend on whether the FDA's ODD or other schemes, or indeed schemes of other regulatory authorities, will contribute grants to help fund the trials.

Cohort 5 has NOT started, unless you want to call gmcc a liar and, by extension, the others that say they've had responses from Alan, including the one who even published the email response on Twitter.

DE 5? Just bl**dy stop and think before you mindlessly post.

Frankly, anyone who thinks the next dose escalation is DE 5 is not worth bothering with. DYOR

What happened to DE4?

If the URL begins www.gov.uk then forget it and save your eyes.

https://www.lse.co.uk/rns/AVCT/therapeutics-chief-development-officer-appointment-j1ytlj279lo7que.html

https://www.lse.co.uk/rns/AVCT/appointment-of-chief-scientific-officer-qheu6lijc7xxty7.html

https://www.businesswire.com/news/home/20230328005510/en/Avacta-Appoints-Karen-Harrison-as-Chief-Operating-Officer-for-Therapeutics-Division

What does a COO do? The COO is a manager with broad responsibilities that range from managing day-to-day operations to providing strategic advice. They oversee daily administrative and operational functions, reporting directly to the CEO and being second only to this person for company affairs.

Just what Avacta needs.

Hard not to think AS has anything but disdain for PIs.

Bashers are out in force today. Great news. The company must be doing something right! Hopefully the bashers can drive the price down for us genuine LTHs to pick up more shares on the cheap.

Yes, a big shout out for Bronte's paid bashers!

Proof reader probably fed up of being single.

That was addressed to DW.